This report examines trispecific T-cell engagers as a strategy for glioblastoma immunotherapy. It evaluates antigen selection criteria, molecular design considerations, and preclinical evidence regarding multi-antigen targeting. Furthermore, it explores innovative delivery mechanisms intended to bypass central nervous system barriers, aiming to establish a modular platform to overcome tumor heterogeneity.
Read more at Acta Neuropathologica.
